https://www.thebodypro.com/category/adverse-events-comorbidities-hiv/tag/conference-coverage

The Latest

Research Shows 47% Reduction in STIs Among Gay Men Who Took Doxycycline After Sex Img

Research Shows 47% Reduction in STIs Among Gay Men Who Took Doxycycline After Sex

The antibiotic, when taken within 72 hours of condomless sex, can reduce the risk of bacterial sexually transmitted infections by 47%, new research presented at CROI this week showed.

Takeaways From the 2016 Liver Meeting for Viral Hepatitis Advocates Img

Takeaways From the 2016 Liver Meeting for Viral Hepatitis Advocates

"It is critical that patients and patient advocates work closely with medical, public health and health economics experts to speak out about our nation's ability to respond to viral hepatitis," Project Inform states.

Colleen Flanigan, RN, M.S.

New York State Hepatitis C Testing Law Increases Screening and Linkage to Care

Hepatitis C testing rates increased significantly following the enactment of the New York State Hepatitis C Testing Law on Jan. 1, 2014, and linkage-to-care rates also increased, a recent study finds.

George Ioannou, M.D., M.S.

All Veterans With Hepatitis C Could Be Cured Within 3 Years

The Department of Veterans Affairs (VA) estimates it can cure the remaining 124,000 patients living with hepatitis C in VA care within the next three years, after record treatment and cure numbers in 2015.

Now That We Have a Cure for Hepatitis C, What Are the Next Treatment Challenges? Img

Now That We Have a Cure for Hepatitis C, What Are the Next Treatment Challenges?

Within the next few years, several pipeline hepatitis C drugs are expected to be approved in the U.S., ensuring that even the most difficult-to-treat patients can be cured -- but what challenges remain?

Mei Lu, Ph.D.

Cirrhosis Increases 40% in Individuals Living With Hepatitis C

The prevalence of liver cirrhosis increased by almost 40% from 2006-2014, going from 20.5% to 28.8%Ed among individuals living with hepatitis C in the U.S.

Stefan Zeuzem, M.D.

Fixed-Dose Sofosbuvir/Velpatasvir/Voxilaprevir Cures 97% of Treatment-Experienced Hepatitis C Patients

Only 6% of 9500 people living with hepatitis C in a U.S. clinic cohort started direct-acting antivirals (DAAs) in 2014 and 2015, according to a recent study.

Low Uptake of Direct-Acting Antivirals for Hepatitis C in U.S. Clinics -- Race and Income Key Factors Img

Low Uptake of Direct-Acting Antivirals for Hepatitis C in U.S. Clinics -- Race and Income Key Factors

Only 6% of 9500 people living with hepatitis C in a U.S. clinic cohort started direct-acting antivirals (DAAs) in 2014 and 2015, according to a recent study.

Curing Hepatitis C Lowers but Does Not Eliminate Risk of Liver Cancer Img

Curing Hepatitis C Lowers but Does Not Eliminate Risk of Liver Cancer

Achieving hepatitis C (HCV) cure with an interferon-based regimen lowered risk of hepatocellular carcinoma (HCC) by 80% in a large Canadian cohort, but cases of HCC still arose after HCV cure.

Treatment With ABT-493/ABT-530 Cures 99% of Patients With Hepatitis C Genotype 2 Img

Treatment With ABT-493/ABT-530 Cures 99% of Patients With Hepatitis C Genotype 2

Almost everyone taking immediate ABT-493/ABT-530 (glecaprevir/pibrentasvir, G/P) in an international placebo-controlled study were cured of hepatitis C, without any serious adverse effects.